IntrinsicIntrinsic
← All summaries

Crinetics Pharmaceuticals, Inc.

CRNX
Financials & Chart →

Business Summary

Crinetics Pharmaceuticals, Inc. is a pharmaceutical company focused on discovering, developing, and commercializing novel therapies for endocrine diseases and endocrine-related tumors, with a core expertise in targeting G protein coupled receptors (GPCRs) with small molecules . The company's business model revolves around generating revenue from product sales and collaboration and licensing arrangements . Product revenue is recorded at wholesale acquisition cost, net of variable consideration and third-party distribution costs, utilizing the expected value method for gross-to-net adjustments . The primary customer segments for its lead product, PALSONIFY, are specialty physicians treating rare diseases in the U.S. .

The company's lead product, PALSONIFY (paltusotine), is the first once-daily, oral treatment approved by the FDA for adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option . Paltusotine is also in clinical development for Carcinoid Syndrome (CS) associated with neuroendocrine tumors (NETs) . The deep pipeline includes atumelnant, an investigational candidate in development for Congenital Adrenal Hyperplasia (CAH) and ACTH-Dependent Cushing's Syndrome (ADCS) , and CRN09682, a nonpeptide drug conjugate (NDC) candidate for SST2 expressing NETs and other SST2 expressing solid tumors . Additional discovery programs target NETs, Graves’ disease (including Graves’ hyperthyroidism and Graves’ orbitopathy, or Thyroid Eye Disease (TED)), polycystic kidney disease, hyperparathyroidism, diabetes, obesity, and GPCR-targeted oncology indications .

For the fiscal year ended December 31, 2025, Crinetics Pharmaceuticals, Inc. reported total revenue, net of $7.696 million , a significant increase from $1.039 million in the prior year. This increase was primarily driven by product revenue, net of $5.420 million , which was generated following the commercial launch of PALSONIFY in October 2025 . Collaboration and license revenue also increased to $2.276 million in 2025 from $1.039 million in 2024, attributed to the timing of revenue recognition for a data exchange performance obligation under the SKK License .

Operating expenses for 2025 totaled $524.465 million , up from $339.893 million in 2024, representing a 54% increase. This rise was due to the inclusion of cost of product revenue of $1.076 million for the first time, reflecting commercial manufacturing readiness, supplier qualification, packaging, distribution, and fulfillment costs . Research and development expenses increased by 38% to $332.058 million from $240.156 million in 2024, driven by the advancement of clinical programs and the preclinical portfolio . Selling, general and administrative expenses saw a 92% increase, reaching $191.331 million in 2025 compared to $99.737 million in 2024, primarily due to increased personnel expenses, stock-based compensation, and professional services supporting the commercial launch of PALSONIFY .

The company reported a net loss of $465.317 million for the year ended December 31, 2025, compared to a net loss of $298.408 million in 2024. Diluted EPS was $(4.95) in 2025, compared to $(3.69) in 2024. Total other income, net, increased to $51.632 million in 2025 from $40.916 million in 2024, primarily due to higher average invested balances and prevailing interest rates on investment securities . The loss on equity method investment was zero in 2025, compared to $0.470 million in 2024, as the investment asset was written down to zero in the prior year .

As of December 31, 2025, cash and cash equivalents were $101.536 million , and investment securities were $926.353 million , totaling $1.027.889 billion in cash, cash equivalents, and investment securities. This represents a decrease from $1.354.069 billion at December 31, 2024. The accumulated deficit grew to $1.417.427 billion as of December 31, 2025, from $952.110 million at December 31, 2024.

Significant operational developments during 2025 include the FDA approval of PALSONIFY on September 25, 2025, as the first once-daily oral somatostatin receptor ligand for acromegaly , with commercial availability in the U.S. starting in October 2025 . The first patient was enrolled in the Phase 3 study of paltusotine for CS in November 2025 . For atumelnant, positive results from the first three cohorts of the Phase 2 TouCAHn open-label study in CAH were reported in January 2025 , and the first participant in the Phase 3 CALM-CAH study was randomized in December 2025 . The BALANCE-CAH pediatric study, an operationally seamless Phase 2/3 study, dosed its first participant in January 2026 . CRN09682 received IND clearance in April 2025 , and the first patient was dosed in its Phase 1/2 study in November 2025 .

Business Outlook

The company expects product revenue to increase in future periods as commercialization efforts for PALSONIFY continue to expand . However, given the early stage of commercialization, product revenue is not expected to be sufficient to offset operating expenses in the near term . The company anticipates continued net losses for the foreseeable future .

A major growth area for the company is the continued commercialization of PALSONIFY in the U.S., where it became commercially available in October 2025 . The company is establishing a specialized commercial organization with sales, marketing, and market access expertise to support the launch, focusing on educating healthcare providers and patients on acromegaly diagnosis, clinical management, and the benefits of PALSONIFY . Efforts include activating patients to request PALSONIFY, educating HCPs to drive prescriber breadth and depth, and engaging with payers to support patient access and formulary inclusion . The company believes PALSONIFY's profile as a once-daily, oral SST2R agonist offering biochemical and symptom control and convenience will provide meaningful differentiation .

Another growth area involves expanding PALSONIFY into additional markets, including the EU, if approved by regulators . In February 2026, the CHMP of the EMA adopted a positive opinion recommending marketing authorization for PALSONIFY for adult acromegaly patients, with a potential EC decision in the first half of 2026 . The company also has an exclusive license agreement with SKK for paltusotine in Japan and may seek additional global licensing or distribution partners for its product candidates . The company also plans to initiate an operationally seamless Phase 2/3 study of atumelnant in ADCS (EQUILIBRIUM-ADCS) in the first half of 2026 .

Operationally, the company expects operating expenses to increase as it continues to invest in commercialization, clinical development, and other research and development activities . Research and development expenses are specifically expected to increase as the pipeline advances and ongoing and planned clinical and preclinical studies are conducted . The cost of product revenue during the initial commercialization period for PALSONIFY was not directly correlated with product revenue, as inventory manufactured prior to regulatory approval had a zero cost basis, and this is not reflective of the expected cost structure for future periods . Selling, general and administrative expenses are also expected to increase to support PALSONIFY's commercialization, expand commercial and administrative infrastructure, and advance research and development activities, including potential commercialization of additional product candidates and expansion into new markets .

Planned capital allocation includes continued investment in research and development programs and product candidates . The company's existing cash, cash equivalents, and investment securities of $1.0 billion as of December 31, 2025, combined with net proceeds of approximately $380.0 million from an underwritten public offering completed on January 8, 2026, resulting in approximately $1.4 billion in cash, cash equivalents, and investment securities, are believed to be sufficient to fund operations for at least the next 12 months . The company plans to continue funding its operations through existing capital resources, product sales, equity offerings, debt financings, or other sources, including potential collaborations and licenses .

Risk Factors

The company faces significant risks, including the inherent uncertainty and high failure rate of preclinical and clinical drug development, where product candidates may fail at any stage or produce unexpected side effects, potentially leading to delays, termination, or denial of regulatory approval . The commercial success of PALSONIFY and other product candidates is uncertain and depends on market acceptance by physicians, patients, and payors, which may be limited by competition, pricing, and reimbursement challenges . The company relies heavily on third parties for clinical trials and manufacturing, and any failure by these parties to meet obligations or comply with regulations could delay development or commercialization . The small patient populations for orphan and rare diseases targeted by the company's products, such as CAH affecting approximately 17,000 people in the U.S. , pose a risk if market opportunities are smaller than estimated, adversely affecting revenue and profitability . Changes in U.S. and international trade policies, including tariffs and export controls, particularly with respect to China and India, could increase manufacturing costs, affect commercialization, and disrupt supply chains . For example, as of February 2026, the US and India agreed to a reciprocal tariff rate of 18 percent on goods imported from India. Cybersecurity threats, including attacks enhanced by artificial intelligence, pose risks of data loss, operational disruption, and reputational harm, despite implemented security measures .

Management Priorities

Management's message to shareholders emphasizes the company's transition from a clinical-stage to a commercial-stage company following the FDA approval and launch of PALSONIFY in September 2025 . They acknowledge the initial period of commercial activity, including product revenue and increased operating expenses, and anticipate continued net losses in the near term despite expected increases in product revenue . A key strategic priority is to successfully commercialize PALSONIFY in the U.S. by establishing a specialized commercial organization, educating healthcare providers and patients, and engaging with payers to support access and formulary inclusion . Another priority is to advance the pipeline, including the ongoing Phase 3 study of paltusotine for CS, the Phase 3 CALM-CAH study for atumelnant, and the initiation of the operationally seamless Phase 2/3 EQUILIBRIUM-ADCS study in the first half of 2026 . The company also aims to expand into additional markets, such as the EU, where the CHMP of the EMA adopted a positive opinion for PALSONIFY in February 2026, with a potential EC decision in the first half of 2026 . Management believes existing capital resources, including approximately $1.4 billion in cash, cash equivalents, and investment securities after a January 2026 public offering, will be sufficient to fund operations for at least the next 12 months .

View Source Annual Report on SEC.gov ↗

References

  1. [1] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  2. [2] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  3. [3] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  4. [4] Item 1, Business — Business Overview
  5. [5] Item 7, MD&A — Financial Operations Overview
  6. [6] Item 7, MD&A — Revenue Recognition - Gross-to-Net Adjustments
  7. [7] Item 1, Business — Sales, Marketing and Distribution
  8. [8] Item 1, Business — Approved Product
  9. [9] Item 1, Business — Approved Product
  10. [10] Item 1, Business — Business Overview
  11. [11] Item 1, Business — Business Overview
  12. [12] Item 1, Business — Business Overview
  13. [13] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  14. [14] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  15. [15] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  16. [16] Item 7, MD&A — Recent Developments
  17. [17] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  18. [18] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  19. [19] Item 7, MD&A — Revenue
  20. [20] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  21. [21] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  22. [22] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  23. [23] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  24. [24] Item 7, MD&A — Cost of product revenue
  25. [25] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  26. [26] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  27. [27] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  28. [28] Item 7, MD&A — Research and development expenses
  29. [29] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  30. [30] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  31. [31] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  32. [32] Item 7, MD&A — Selling, general and administrative expenses
  33. [33] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  34. [34] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  35. [35] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  36. [36] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  37. [37] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  38. [38] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  39. [39] Item 7, MD&A — Other income
  40. [40] Item 7, MD&A — Results of Operations Comparison of the years ended December 31, 2025 and 2024
  41. [41] Item 7, MD&A — Loss on equity method investment
  42. [42] Item 7, MD&A — Liquidity and Capital Resources
  43. [43] Item 7, MD&A — Liquidity and Capital Resources
  44. [44] Item 7, MD&A — Liquidity and Capital Resources
  45. [45] Item 7, MD&A — Liquidity and Capital Resources
  46. [46] Item 7, MD&A — Liquidity and Capital Resources
  47. [47] Item 7, MD&A — Liquidity and Capital Resources
  48. [48] Item 7, MD&A — Recent Developments
  49. [49] Item 1, Business — Our Strategy
  50. [50] Item 7, MD&A — Recent Developments
  51. [51] Item 7, MD&A — Recent Developments
  52. [52] Item 7, MD&A — Recent Developments
  53. [53] Item 7, MD&A — Recent Developments
  54. [54] Item 7, MD&A — Recent Developments
  55. [55] Item 7, MD&A — Recent Developments
  56. [56] Item 7, MD&A — Financial Operations Overview
  57. [57] Item 7, MD&A — Financial Operations Overview
  58. [58] Item 7, MD&A — Financial Operations Overview
  59. [59] Item 1, Business — Our Strategy
  60. [60] Item 1, Business — Our Strategy
  61. [61] Item 1, Business — Our Strategy
  62. [62] Item 1, Business — Our Strategy
  63. [63] Item 1, Business — Our Strategy
  64. [64] Item 1, Business — Key Pipeline Updates
  65. [65] Item 1, Business — Our Strategic Collaborations
  66. [66] Item 1, Business — Our Strategy
  67. [67] Item 1, Business — Key Pipeline Updates
  68. [68] Item 7, MD&A — Financial Operations Overview
  69. [69] Item 7, MD&A — Research and development expenses
  70. [70] Item 7, MD&A — Cost of product revenue
  71. [71] Item 7, MD&A — Selling, general and administrative expenses
  72. [72] Item 7, MD&A — Liquidity and Capital Resources
  73. [73] Item 7, MD&A — Liquidity and Capital Resources
  74. [74] Item 7, MD&A — Equity Offerings
  75. [75] Item 7, MD&A — Liquidity and Capital Resources
  76. [76] Item 7, MD&A — Liquidity and Capital Resources
  77. [77] Item 7, MD&A — Liquidity and Capital Resources
  78. [78] Item 1A, Risk Factors — Risks related to the discovery and development and regulatory approval of our product candidates and the commercialization of PALSONIFY
  79. [79] Item 1A, Risk Factors — Risks related to commercialization of PALSONIFY and our product candidates
  80. [80] Item 1A, Risk Factors — Risks related to our reliance on third parties
  81. [81] Item 1, Business — CAH Disease Background
  82. [82] Item 1A, Risk Factors — Risks related to commercialization of PALSONIFY and our product candidates
  83. [83] Item 1A, Risk Factors — Risks related to the discovery and development and regulatory approval of our product candidates and the commercialization of PALSONIFY
  84. [84] Item 1A, Risk Factors — Risks related to the discovery and development and regulatory approval of our product candidates and the commercialization of PALSONIFY
  85. [85] Item 1A, Risk Factors — General risk factors
  86. [86] Item 7, MD&A — Overview
  87. [87] Item 7, MD&A — Financial Operations Overview
  88. [88] Item 1, Business — Our Strategy
  89. [89] Item 1, Business — Key Pipeline Updates
  90. [90] Item 1, Business — Key Pipeline Updates
  91. [91] Item 7, MD&A — Liquidity and Capital Resources
  92. [92] Item 7, MD&A — Liquidity and Capital Resources

Analysis on 5/22/2026